Literature DB >> 10715374

Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles.

H Ishikawa1, Y Mitsui, T Yoshitomi, K Mashimo, S Aoki, K Mukuno, K Shimizu.   

Abstract

PURPOSE: To investigate the effects of botulinum toxin type A (botulinum A toxin) on the autonomic and other nonadrenergic, noncholinergic nerve terminals.
METHODS: The effects of botulinum A toxin on twitch contractions evoked by electrical field stimulation (EFS) were studied in isolated albino and pigmented rabbit iris sphincter and dilator muscles using the isometric tension recording method.
RESULTS: Botulinum A toxin inhibited the fast cholinergic and slow substance P-ergic component of the contraction evoked by EFS in the rabbit iris sphincter muscle without affecting the response to carbachol and substance P. These inhibitory effects were more marked in the albino rabbit than in the pigmented rabbit. Botulinum A toxin (150 nmol/L) did not affect the twitch contraction evoked by EFS in the rabbit iris dilator muscle.
CONCLUSIONS: These data indicated that botulinum A toxin may inhibit not only the acetylcholine release in the cholinergic nerve terminals, but also substance P release from the trigeminal nerve terminals of the rabbit iris sphincter muscle. However, the neurotoxin has little effect on the adrenergic nerve terminals of the rabbit iris dilator muscle. Furthermore, the botulinum A toxin binding to the pigment melanin appears to influence the response quantitatively in the two types of irides.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10715374     DOI: 10.1016/s0021-5155(99)00197-5

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  30 in total

1.  [Pharmacology of botulinum toxin drugs].

Authors:  D Dressler
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

Review 2.  Botulinum neurotoxin - from laboratory to bedside.

Authors:  K A Foster; H Bigalke; K R Aoki
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 3.  [Pharmacological aspects of therapeutic botulinum toxin preparations].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 4.  Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms.

Authors:  Catherine A Thomas; Yao-Chi Chuang; Antonella Giannantoni; Michael B Chancellor
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 5.  Botulinum toxin for pain.

Authors:  Roberto Casale; Valeria Tugnoli
Journal:  Drugs R D       Date:  2008

Review 6.  Treatment of chronic low back pain with botulinum neurotoxins.

Authors:  Bahman Jabbari
Journal:  Curr Pain Headache Rep       Date:  2007-10

7.  Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study.

Authors:  Larissa Bittencourt da Silva; Ali Karshenas; Flemming Winther Bach; Sten Rasmussen; Lars Arendt-Nielsen; Parisa Gazerani
Journal:  Pain Res Manag       Date:  2014 May-Jun       Impact factor: 3.037

Review 8.  Evidence based medicine on the use of botulinum toxin for headache disorders.

Authors:  W J Schulte-Mattler; E Leinisch
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

Review 9.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

Review 10.  Botulinum toxin therapy for myofascial pain disorders.

Authors:  Amy M Lang
Journal:  Curr Pain Headache Rep       Date:  2002-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.